DekaBank Deutsche Girozentrale
LCTX icon

DekaBank Deutsche Girozentrale’s Lineage Cell Therapeutics LCTX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-402,100
Closed -$607K – 1400
2022
Q1 		$607K Buy
402,100
+36,600
+10% +$56.8K ﹤0.01% 1025
2021
Q4 		$887K Sell
365,500
-184,500
-34% -$432K ﹤0.01% 961
2021
Q3 		$1.39M Hold
550,000
– – ﹤0.01% 821
2021
Q2 		$1.59M Buy
+550,000
New +$1.42M ﹤0.01% 782

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

DekaBank Deutsche Girozentrale's LCTX Position: Q2 2022 in Review

DekaBank Deutsche Girozentrale sold out of Lineage Cell Therapeutics (LCTX) in Q2 2022, closing a stake of 402,100 shares — an estimated $607K sold.

DekaBank Deutsche Girozentrale first reported a position in LCTX in Q2 2021 and held it in 4 quarters. The position peaked at $1.59M in Q2 2021. 101 funds tracked by Wall St. Rank hold LCTX as of Q2 2022.

  • DekaBank Deutsche Girozentrale reported no remaining Lineage Cell Therapeutics position as of Q2 2022 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 402,100 Lineage Cell Therapeutics shares in Q2 2022, an estimated $607K.
  • DekaBank Deutsche Girozentrale first reported a position in Lineage Cell Therapeutics in Q2 2021 and held it in 4 quarters.
  • DekaBank Deutsche Girozentrale's Lineage Cell Therapeutics position peaked at $1.59M in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2022.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2022, filed 3 Aug 2022.